Twin City Private Wealth LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Twin City Private Wealth LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,132 shares of the biopharmaceutical company’s stock after selling 5,160 shares during the quarter. Twin City Private Wealth LLC’s holdings in Pfizer were worth $1,065,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Swedbank AB increased its position in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after buying an additional 37,636 shares during the period. United Bank increased its position in Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares during the period. Segall Bryant & Hamill LLC acquired a new position in Pfizer during the third quarter worth approximately $2,123,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Pfizer by 67.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 5,959 shares during the period. Finally, Stonebrook Private Inc. acquired a new position in Pfizer during the third quarter worth approximately $208,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1 %

Shares of PFE stock opened at $26.20 on Monday. The business’s fifty day moving average price is $26.17 and its 200 day moving average price is $27.04. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $148.61 billion, a PE ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.